Author
Listed:
- Jacob E. Till
(Abramson Cancer Center of the University of Pennsylvania)
- Lee McDaniel
(Inc.)
- Changgee Chang
(Indiana University School of Medicine)
- Qi Long
(Abramson Cancer Center of the University of Pennsylvania)
- Shannon M. Pfeiffer
(Parker Institute for Cancer Immunotherapy)
- Jaclyn P. Lyman
(Parker Institute for Cancer Immunotherapy)
- Lacey J. Padrón
(Parker Institute for Cancer Immunotherapy)
- Deena M. Maurer
(Parker Institute for Cancer Immunotherapy)
- Jia Xin Yu
(Parker Institute for Cancer Immunotherapy)
- Christine N. Spencer
(Parker Institute for Cancer Immunotherapy)
- Pier Federico Gherardini
(Parker Institute for Cancer Immunotherapy)
- Diane M. Silva
(Parker Institute for Cancer Immunotherapy)
- Theresa M. LaVallee
(Parker Institute for Cancer Immunotherapy)
- Charles Abbott
(Inc.)
- Richard O. Chen
(Inc.)
- Sean M. Boyle
(Inc.)
- Neha Bhagwat
(Abramson Cancer Center of the University of Pennsylvania)
- Samuele Cannas
(Abramson Cancer Center of the University of Pennsylvania)
- Hersh Sagreiya
(Abramson Cancer Center of the University of Pennsylvania)
- Wenrui Li
(Abramson Cancer Center of the University of Pennsylvania)
- Stephanie S. Yee
(Abramson Cancer Center of the University of Pennsylvania)
- Aseel Abdalla
(Abramson Cancer Center of the University of Pennsylvania)
- Zhuoyang Wang
(Abramson Cancer Center of the University of Pennsylvania)
- Melinda Yin
(Abramson Cancer Center of the University of Pennsylvania)
- Dominique Ballinger
(Abramson Cancer Center of the University of Pennsylvania)
- Paul Wissel
(Abramson Cancer Center of the University of Pennsylvania)
- Jennifer Eads
(Abramson Cancer Center of the University of Pennsylvania)
- Thomas Karasic
(Abramson Cancer Center of the University of Pennsylvania)
- Charles Schneider
(Abramson Cancer Center of the University of Pennsylvania)
- Peter O’Dwyer
(Abramson Cancer Center of the University of Pennsylvania)
- Ursina Teitelbaum
(Abramson Cancer Center of the University of Pennsylvania)
- Kim A. Reiss
(Abramson Cancer Center of the University of Pennsylvania)
- Osama E. Rahma
(Dana-Farber Cancer Institute)
- George A. Fisher
(Stanford University)
- Andrew H. Ko
(San Francisco)
- Zev A. Wainberg
(Los Angeles)
- Robert A. Wolff
(The University of Texas MD Anderson Cancer Center)
- Eileen M. O’Reilly
(Memorial Sloan Kettering Cancer Center)
- Mark H. O’Hara
(Abramson Cancer Center of the University of Pennsylvania)
- Christopher R. Cabanski
(Parker Institute for Cancer Immunotherapy)
- Robert H. Vonderheide
(Abramson Cancer Center of the University of Pennsylvania)
- Erica L. Carpenter
(Abramson Cancer Center of the University of Pennsylvania)
Abstract
While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here we investigate KRAS ctDNA (ctKRAS) variant-specific associations with overall and progression-free survival (OS/PFS) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for patients receiving chemoimmunotherapy (“PRINCE”, NCT03214250), and an independent cohort receiving standard of care (SOC) chemotherapy. For PRINCE, higher baseline plasma levels are associated with worse OS for ctKRAS G12D (log-rank p = 0.0010) but not G12V (p = 0.7101), even with adjustment for clinical covariates. Early, on-therapy clearance of G12D (p = 0.0002), but not G12V (p = 0.4058), strongly associates with OS for PRINCE. Similar results are obtained for the SOC cohort, and for PFS in both cohorts. These results suggest ctKRAS G12D but not G12V as a promising prognostic biomarker for mPDAC and that G12D clearance could also serve as an early biomarker of response.
Suggested Citation
Jacob E. Till & Lee McDaniel & Changgee Chang & Qi Long & Shannon M. Pfeiffer & Jaclyn P. Lyman & Lacey J. Padrón & Deena M. Maurer & Jia Xin Yu & Christine N. Spencer & Pier Federico Gherardini & Dia, 2024.
"Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma,"
Nature Communications, Nature, vol. 15(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49915-5
DOI: 10.1038/s41467-024-49915-5
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49915-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.